Skip to main content
. 2022 Mar 15;13(3):514. doi: 10.3390/genes13030514

Table 2.

Clinical signs reported in patients with a KMT2A mutation and an initial clinical diagnosis of chromatinopathy. Presence of all features is compared with the one in WDSTS.

WDSTS CdLS CSS KS RSTS
[26] 1 + 1 pt [35,36] 1 pt [29] 2 pt [31] 1 + 6 pt [26,37]
Vision problems 0/2 1/1 1/2 1/7
Cardiac problems + 1/2 1/1 1/2 0/7
CNS problems +/− 1/2 0/1 NA 0/7
Genitourinary problems 0/2 1/1 1/2 2/7
Feeding problems + 0/2 1/1 1/2 3/7
Behavior problems + 1/2 0/1 NA 3/7
Frequent infection 0/2 1/1 1/2 0/7
Seizures +/− 0/2 0/1 1/2 1/7
ID ++ 2/2 1/1 1/2 7/7
Speech delay ++ 1/2 1/1 NA 5/7
Microcephaly 2/2 NA NA 3/7
Eyes anomalies (thick eyebrows, synophrys, long eyelashes, ptosis, downslanting/narrow palpebral fissure) + 2/2 1/1 2/2 7/7
Nose anomalies (depressed nasal bridge, broad nasal tip) + 2/2 1/1 2/2 7/7
Mouth anomalies (high arched palate, thin upper vermilion) +/− 2/2 1/1 0/2 4/7
Hands/feet anomalies (clinodactyly, brachydactyly, persistent fetal finger pads, broad halluces) +/− 2/2 1/1 2/2 6/7
Delayed bone age + 0/2 NA NA 0/7
Hirsutism + 1/2 1/1 NA 4/7
Hypotonia ++ NA 1/1 2/2 3/7

WDSTS: Wiedemann–Steiner syndrome, CdLS: Cornelia De Lange syndrome, CSS: Coffin–Siris syndromes, KS: Kabuki syndrome, RSTS: Rubinstein–Taybi syndrome, CNS: Central nervous system, ID: intellectual disability. ++ = 70–100% WDSTS patients; + = 20–70% WDSTS patients; +/− = 5–20% WDSTS patients; − = <5% WDSTS patients; NA = not assessed.